http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Phase III Efficacy Results of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced by Exploratory Analyses in Two Forms of Multiple Sclerosis
-
Foundation Medicine to Present at the Morgan Stanley Global Healthcare Conference
-
Foundation Medicine Adds New Immunotherapy Features to Its Market-Leading Products
-
Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights
-
FoundationOne® Accepted by FDA and CMS for Parallel Review and FDA Expedited Access Pathway
-
Genomics Leaders to Speak at Inaugural Precision Medicine Leaders Summit in San Diego
-
Genomics Leaders to Speak at Inaugural Precision Medicine Leaders Summit in San Diego
-
Foundation Medicine Announces Timing for Second Quarter 2016 Financial Results and Conference Call
-
Study Recommends Genomic Profiling to Diagnose Nonsmall Cell Lung Cancer Subtypes
-
Foundation Medicine Announces Release of Molecular Information from FoundationCORE™ to the National Cancer Institute in Support of the National Cancer Moonshot and Precision Medicine Initiatives
-
New Data from Foundation Medicine and Collaborators Supports Use of Comprehensive Genomic Profiling to Inform Therapeutic Choices in Advanced Breast Cancer
-
Data From a Study Utilizing FoundationOne® Heme Indicates Age-Associated Genomic Profiles in Acute Myeloid Leukemia
-
Foundation Medicine Presents New Data at ASCO 2016 Demonstrating that FoundationOne® May Help Predict Response to Cancer Immunotherapy Across a Variety of Advanced Cancers
-
FoundationOne® Identifies Patients with Advanced Lung Cancer Likely to Respond or Develop Resistance to Certain RET Inhibitor Therapies
-
Foundation Medicine and AstraZeneca Enter Strategic Collaboration for Lynparza Companion Diagnostic Assay
-
Foundation Medicine to Present at the Goldman Sachs Annual Healthcare Conference
-
Foundation Medicine (FMI) Says ASCO 2016 Presentations Will Happen; Offers Details
-
Foundation Medicine Announces Presentations at ASCO
-
Roche (RHHBY) Announces FDA Approval of VENTANA PD-L1 Assay
-
Roche receives FDA Approval for novel PD-L1 biomarker assay
-
Foundation Medicine Receives Patent Covering Fundamental Methods in Comprehensive Genomic Analysis in Cancer
-
Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights
-
Foundation Medicine Announces Commercial Launch of Liquid Biopsy Assay, FoundationACT™
-
Foundation Medicine and AstraZeneca Collaborate to Develop Companion Diagnostic Assays in Oncology
-
Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Foundation Medicine to Present at Upcoming Investor Conferences
-
COTA, Inc. to Speak at the Vatican's 2016 Cellular Horizons Conference
-
The Vatican Hosts Third International Regenerative Medicine Conference
-
CORRECTING and REPLACING The Vatican Hosts Third International Regenerative Medicine Conference
-
Anomali Lands $30 Million in Series C Funding Led by Institutional Venture Partners
-
Foundation Medicine’s Molecular Information Supports Discovery of Precision Therapeutics for Pediatric Cancers
-
Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine Ocrelizumab Versus Comparators on Disease Activity and Progression in Two Forms of Multiple Sclerosis
-
AbbVie (ABBV) Announces Receipt of Accelerated FDA Approval for Venclexta in CLL
-
Foundation Medicine Announces Timing for First Quarter 2016 Financial Results and Conference Call
-
New Data with FoundationOne® Supports Clinical Utility and Improved Outcomes from Molecularly Matching Non-Small Cell Lung Cancer Patients to Targeted Therapy
-
Foundation Medicine and Memorial Sloan Kettering Publish Validation Data for FoundationOne® Heme in the Journal Blood
-
Kite Pharma (KITE), Genentech Enter Collaboration to Evaluate KTE-C19 + Atezolizumab in NHL (RHHBY)
-
Foundation Medicine Announces Presentations at the AACR Annual Meeting 2016
-
Foundation Medicine Presents New Data at the 2016 USCAP Annual Meeting Underscoring Importance of Comprehensive Genomic Profiling in Cancer Care
-
Foundation Medicine to Present at Cowen and Company’s 36th Annual Healthcare Conference
-
AbbVie (ABBV) Announces Receipt of EMA Orphan Drug Designation for Venetoclax as AML Treatment
-
Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE™ to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers
-
Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook
-
Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2015 Financial Results and Conference Call
-
Foundation Medicine to Present at the Leerink Global Healthcare Conference
-
Foundation Medicine, Horizon Healthcare Services, Inc. and COTA Collaborate to Demonstrate the Benefits of a Precision Medicine Treatment Approach for Patients with Metastatic Non-Small Cell Lung Canc
-
Foundation Medicine (FMI) Prelim. Q4, FY15 Revenue Exceeds Expectations
-
Foundation Medicine Reports Preliminary 2015 Results and Provides 2016 Business Outlook, including Commercial Launch of its ctDNA Assay
-
Foundation Medicine Announces Presentations at the 2016 Genitourinary Cancers Symposium
-
Foundation Medicine to Present at the 34th Annual J.P. Morgan Healthcare Conference
